7-溴-5-氯-1H-吲唑 | 875305-86-5

• 物质功能分类: 有机原料 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡唑类
• 中文名称: 7-溴-5-氯-1H-吲唑
• 英文名称: 7-bromo-5-chloro-1H-indazole
• CAS: 875305-86-5
• 化学式: C₇H₄BrClN₂
• 分子量: 231.479
• InChiKey: CTXAUTRSBNWONT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  28.7
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 危险品标志：
  Xi
• 海关编码：
  2933990090

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 7-Bromo-5-chloro-1H-indazole
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 7-Bromo-5-chloro-1H-indazole
CAS number: 875305-86-5

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C7H4BrClN2
Molecular weight: 231.5

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  7-溴-5-氯-1H-吲唑 在 1,1'-双(二苯膦基)二茂铁二氯化钯(II)二氯甲烷复合物 、 potassium acetate 、 sodium carbonate 、 potassium carbonate 作用下， 以 1,4-二氧六环 、 乙二醇二甲醚 、 乙醇 、 水 、 二甲基亚砜 为溶剂， 反应 4.0h， 生成 5-chloro-7-(6-methoxypyrimidin-4-yl)-1-methyl-1H-indazole
  参考文献：
  名称：

  [EN] MACROCYCLES WITH HETROCYCLIC P2' GROUPS AS FACTOR XIA INHIBITORS
  [FR] MACROCYCLES À GROUPES HÉTÉROCYCLIQUES P2' SERVANT D'INHIBITEURS DU FACTEUR XIA

  摘要：

  本发明提供了式(I)的化合物：或其立体异构体、互变异构体或药学上可接受的盐，其中所有变量如本文所定义。这些化合物是选择性因子XIa抑制剂或FXIa和血浆激肽酶的双重抑制剂。本发明还涉及包含这些化合物的药物组合物以及使用它们治疗血栓栓塞和/或炎症性疾病的方法。

  公开号：

  WO2015116886A1
• 作为产物：
  描述：

  4-氯-2-甲基苯胺 在 盐酸 、 sodium nitrite 、 sodium acetate 、 potassium tert-butylate 、 叔丁基硫醇 作用下， 以 水 为溶剂， 反应 0.5h， 以54%的产率得到7-溴-5-氯-1H-吲唑
  参考文献：
  名称：

  Substituted Heterocyclic Ethers and Their Use in CNS Disorders

  摘要：

  这项发明涵盖了公式I的化合物，包括药用盐、它们的药物组合物以及它们在治疗中枢神经系统疾病中的用途。

  公开号：

  US20090018132A1

文献信息

• [EN] HETEROCYCLIC COMPOUNDS, COMPOSITIONS COMPRISING HETEROCYCLIC COMPOUND, AND METHODS OF USE THEREOF<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES, COMPOSITIONS COMPRENANT LE COMPOSÉ HÉTÉROCYCLIQUE, ET LEURS PROCÉDÉS D'UTILISATION
  申请人：JS INNOPHARM SHANGHAI LTD

  公开号：WO2019076358A1

  公开（公告）日：2019-04-25

  Disclosed herein are compounds of formula I and/or a stereoisomer, stable isotopologue, and/or pharmaceutically acceptable salts thereof; and therapeutic uses of these compounds, which are inhibitors of tryptophan 2, 3-dioxygenase 2 (TDO2) and/or indoleamine 2, 3-dioxygenase 1 (IDO1), potentially useful in the treatment of diseases treatable, such as cancers.

  披露的是公式I的化合物和/或立体异构体、稳定同位素和/或其药物可接受的盐；以及这些化合物的治疗用途，这些化合物是色氨酸2,3-二氧酶2（TDO2）和/或吲哚胺2,3-二氧酶1（IDO1）的抑制剂，可能在治疗可治疗的疾病，如癌症中有潜在用途。
• Indole, indazole and indoline derivatives as CETP inhibitors
  申请人：Conte-Mayweg Aurelia

  公开号：US20060030613A1

  公开（公告）日：2006-02-09

  The present invention relates to compounds of formula (I): wherein —X—Y—, R 1 to R 11 and n are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prevention of diseases which are mediated by CETP inhibitors.

  本发明涉及以下式(I)的化合物： 其中-X-Y-, R1至R11和n如描述和权利要求中所定义，并且其药学上可接受的盐。这些化合物对于治疗和/或预防通过CETP抑制剂介导的疾病是有用的。
• [EN] COMPOUNDS AND METHODS FOR IDO AND TDO MODULATION, AND INDICATIONS THEREFOR<br/>[FR] COMPOSÉS ET PROCÉDÉS DE MODULATION D'IDO ET DE TDO, ET INDICATIONS POUR CEUX-CI
  申请人：PLEXXIKON INC

  公开号：WO2019183145A1

  公开（公告）日：2019-09-26

  Disclosed are compounds of Formula (I) and (Ia) or a pharmaceutically acceptable salt, a solvate, a tautomer, a stereoisomer or a deuterated analog thereof, wherein R4, R5, R6, and R7 are as described in any of the embodiments described in this disclosure; compositions thereof; and uses thereof.

  本公开了化合物的结构式（I）和（Ia），或其药用盐、溶剂合物、互变异构体、立体异构体或重氘化类似物，其中R4、R5、R6和R7如本公开所述的各实施例中所述；其组合物；以及其用途。
• Unprotected Indazoles Are Resilient to Ring-Opening Isomerization: A Case Study on Catalytic C–S Couplings in the Presence of Strong Base
  作者：Jacob M. Ganley、Charles S. Yeung

  DOI：10.1021/acs.joc.7b02712

  日期：2017.12.15

  Indazoles represent a privileged scaffold in medicinal chemistry. In the presence of strong base, however, N-protected indazoles are prone to an undesirable ring-opening reaction to liberate o-aminobenzonitriles. By employing unprotected indazoles with a free N–H bond, isomerization is averted because the heterocycle is deprotonated in situ. We herein report functional group-tolerant and robust C–S

  吲唑是药物化学中的一种特殊支架。然而，在强碱的存在下，N-保护的吲唑易于发生不希望的开环反应以释放邻氨基苯甲腈。通过使用带有NH键的未保护的吲唑，由于杂环被原位去质子化，因此可以避免异构化。我们在本文中报道了在双（三甲基甲硅烷基）酰胺锂存在下，溴吲唑与具有不同电子性质的硫醇的官能团耐受性和稳健的C–S偶联。
• PYRIMIDINONES AS FACTOR XIA INHIBITORS
  申请人：Bristol-Myers Squibb Company

  公开号：US20200055854A1

  公开（公告）日：2020-02-20

  The present invention provides compounds of Formula (1): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.

  本发明提供了式（1）的化合物：或其立体异构体，互变异构体或其药学上可接受的盐，其中所有变量均如本文所定义。这些化合物是选择性因子XIa抑制剂或FXIa和血浆卡利肌酶的双重抑制剂。本发明还涉及包含这些化合物的药物组合物以及使用它们治疗血栓栓塞性和/或炎症性疾病的方法。